'Suicidal ideation' leads to end of Amgen-AstraZeneca drug partnership

Amgen has pulled out of a co-development deal it had with AstraZeneca for an experimental psoriasis drug, which was in the late stages of clinical development, after observing “suicidal ideation” in some patients during clinical testing of the new drug candidate...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.